Karyopharm Therapeutics (KPTI) Short-term Investments (2014 - 2026)

Karyopharm Therapeutics (KPTI) has 12 years of Short-term Investments data on file, last reported at $3.2 million in Q4 2025.

• Quarterly Short-term Investments fell 93.07% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.2 million (down 93.07% YoY) and the FY2025 annual result came in at $3.2 million, down 93.07% from the prior year.
• Short-term Investments declined to $3.2 million in Q4 2025, from $8.2 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $176.3 million in Q1 2023 to a low of $3.2 million in Q4 2025.
• A 5-year average of $84.0 million and a median of $72.2 million in 2022 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments surged 274.2% — and 2025, when it slumped 93.07%.
• Tracing KPTI's Short-term Investments over 5 years: stood at $38.2 million in 2021, then surged by 274.2% to $142.8 million in 2022, then slipped by 2.5% to $139.2 million in 2023, then slumped by 66.79% to $46.2 million in 2024, then tumbled by 93.07% to $3.2 million in 2025.
• The last three Short-term Investments figures came in at $3.2 million (Q4 2025), $8.2 million (Q3 2025), and $13.0 million (Q2 2025), per Business Quant data.